Point72 Hong Kong LTD Ligand Pharmaceuticals Inc Transaction History

Point72 Hong Kong LTD

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.01 - $107.56 $6 - $73,140	680 New	680 $59,000
Q1 2022 May 16, 2022	SELL	$94.99 - $151.56 $12,348 - $19,702	-130 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$127.69 - $165.85 $16,599 - $21,560	130 New	130 $20,000
Q2 2021 Aug 16, 2021	SELL	$113.03 - $155.64 $24,301 - $33,462	-215 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $26,969 - $58,489	-271 Reduced 55.76%	215 $33,000
Q4 2020 Feb 16, 2021	BUY	$80.55 - $106.05 $16,512 - $21,740	205 Added 72.95%	486 $48,000
Q3 2020 Nov 16, 2020	BUY	$89.56 - $126.72 $25,166 - $35,608	281 New	281 $27,000
Q2 2020 Aug 14, 2020	SELL	$68.28 - $123.65 $8,603 - $15,579	-126 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$63.37 - $107.88 $7,984 - $13,592	126 New	126 $9,000
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $1,454 - $1,703	-15 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $1,638 - $2,283	-19 Reduced 55.88%	15 $1,000
Q2 2019 Aug 14, 2019	BUY	$107.38 - $129.34 $3,650 - $4,397	34 New	34 $4,000
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $741 - $997	-7 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $898 - $1,904	7 New	7 $1,000

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.